Robeco Institutional Asset Management B.V. Reduces Stock Position in Biogen Inc. $BIIB

Robeco Institutional Asset Management B.V. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB) by 9.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 610,908 shares of the biotechnology company’s stock after selling 60,146 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.42% of Biogen worth $107,514,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of BIIB. Accredited Wealth Management LLC increased its holdings in Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 185 shares during the period. WFA of San Diego LLC bought a new stake in Biogen during the 2nd quarter worth approximately $32,000. True Wealth Design LLC increased its holdings in Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 90 shares during the period. GoalVest Advisory LLC bought a new stake in Biogen during the 4th quarter worth approximately $35,000. Finally, Elevation Wealth Partners LLC increased its holdings in Biogen by 412.8% during the 4th quarter. Elevation Wealth Partners LLC now owns 200 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 161 shares during the period. Institutional investors own 87.93% of the company’s stock.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.18% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Stifel Nicolaus increased their price target on shares of Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Truist Financial increased their price target on shares of Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a report on Monday, February 9th. Morgan Stanley increased their price target on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a report on Friday. HC Wainwright increased their price target on shares of Biogen from $228.00 to $237.00 and gave the stock a “buy” rating in a report on Thursday, April 2nd. Finally, Piper Sandler increased their price target on shares of Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Biogen has a consensus rating of “Hold” and a consensus price target of $207.92.

Biogen Price Performance

Shares of Biogen stock opened at $172.97 on Monday. The firm has a market cap of $25.39 billion, a PE ratio of 19.63, a price-to-earnings-growth ratio of 2.31 and a beta of 0.16. Biogen Inc. has a 12-month low of $112.18 and a 12-month high of $202.41. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The company’s fifty day simple moving average is $186.59 and its two-hundred day simple moving average is $172.95.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company’s revenue was down 7.2% on a year-over-year basis. During the same quarter last year, the firm earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities analysts expect that Biogen Inc. will post 15.83 EPS for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.